AI Image
GLP-1 injections recalled nationwide over sterility concerns
Fox Business • • business
Key Points:
- Apothecary Pharma is voluntarily recalling 23 vials of injectable drugs nationwide due to concerns about sterility, including 22 vials of compounded tirzepatide and one vial of NAD+ injection.
- The FDA classified the recall as Class II on October 8, indicating that serious health consequences are unlikely, but patients may still be at risk.
- The recall follows a December 2025 FDA warning letter citing serious deficiencies in Apothecary Pharma's sterile drug production practices, though no direct link to the current recall has been established.
- Affected tirzepatide lots have beyond-use dates from October 7 to November 26, 2026, and the NAD+ injection lot expires on October 13, 2026; consumers are advised to stop using these products and consult their healthcare providers.
- No illnesses or injuries have been reported in connection with the recall, which remains ongoing as Apothecary Pharma continues to notify recipients.
